Discovering CCDC65: A Potential Drug Target and Biomarker (G85478)

Target Name: CCDC65

NCBI ID: G85478

CCDC65

Discovering CCDC65: A Potential Drug Target and Biomarker

CCDC65, also known as FAP250, is a protein that is expressed in various tissues throughout the body. It is a member of the family of scaffold proteins, which are involved in the formation of tissues and organs during development. CCDC65 has been identified as a potential drug target and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery and characterization of CCDC65 was made by a team of researchers at the University of California, San Diego. The team identified CCDC65 as a protein that is expressed in a variety of tissues, including the brain, heart, liver, and pancreas. They also showed that CCDC65 was involved in the formation of new tissues during development, and that it was required for the development and maintenance of tissues.

Since its discovery, CCDC65 has been shown to be involved in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most promising aspects of CCDC65 is its potential as a drug target.

CDC65 has been shown to be involved in the development and progression of cancer. For example, studies have shown that high levels of CCDC65 are associated with poor prognosis in patients with pancreatic cancer. Additionally, CCDC65 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential role in cancer and neurodegenerative diseases, CCDC65 has also been shown to be involved in autoimmune disorders. For example, studies have shown that CCDC65 is involved in the development of rheumatoid arthritis, a type of autoimmune disorder.

The potential uses of CCDC65 as a drug target are vast. Because CCDC65 is involved in the formation of tissues and organs during development, it may be a useful target for drugs that are designed to stimulate the growth and development of new tissues. Additionally, because CCDC65 is involved in the development and progression of cancer, it may be a useful target for drugs that are designed to inhibit the growth and spread of cancer cells.

In addition to its potential as a drug target, CCDC65 has also been shown to be a valuable biomarker. Because CCDC65 is expressed in a variety of tissues throughout the body, it may be a useful biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overall, CCDC65 is a protein that has the potential to be a valuable drug target and biomarker. Further research is needed to fully understand its role in these diseases and to develop treatments that can effectively target CCDC65.

Protein Name: Coiled-coil Domain Containing 65

Functions: Component of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes (By similarity). Plays a critical role in the assembly of N-DRC and also stabilizes the assembly of multiple inner dynein arms and radial spokes. Coassembles with DRC1 to form a central scaffold needed for assembly of the N-DRC and its attachment to the outer doublet microtubules (PubMed:24094744)

The "CCDC65 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC65 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets